not with ISIM just sitting there, very frustrated with that stock right now
not with ISIM just sitting there, very frustrated with that
Top 10 Most Recent News Articles
Cove Capital Secures $9.96M for Debt-Free Logistics DST
Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...
Continue Reading
Sacrifice Unending: 9/11's Lingering Health Toll
The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...
Continue Reading
Deadline Looms for EquipmentShare Investors' Legal Action
Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....
Continue Reading
Mobile Iron IV Expansions: Targeting Texas Health Needs
Out in Texas, folks facing iron deficiency have a new game-changer coming their way. Drip Gym, the same outfit making waves out in Queens and Long Island, is taking their mobile iron IV therapy clinic straight to Texan doorsteps. No more trotting off to a clinic for iron infusions with this crew rolling into Houston, Dallas, Austin, and San Antonio. What's the Big Deal?...
Continue Reading
AI Trust in Finance: Survey Reveals Market Impact
Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....
Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care
Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...
Continue Reading
WNET's 25th Anniversary 9/11 Tribute: Stories and Lessons
Reflecting on a Dark Day with WNET's Programming Nothing quite hits you like the anniversary of a colossal tragedy. The memories of September 11, 2001, remain etched in the urban landscape of New York City, and this year marks 25 years since that heart-wrenching day. The WNET Group steps up to the plate with a comprehensive slate of programming aimed at honoring the...
Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies
Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...
Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth
Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...
Continue Reading
Midlife ADHD in Women: New Challenges and Solutions
ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...
Continue ReadingTop 5 Most Recently Viewed Articles
Revolutionizing Views: Space Needle's New Otis Elevators
Space Needle Unveils Modern Otis Double-Deck Elevators In a significant upgrade to enhance visitor experiences, the Space Needle has launched its first Otis double-deck glass elevator. This innovative lift is part of a larger project to modernize three elevators at the iconic structure, providing a unique ride with stunning panoramic views. A First Look at the Innovative...
Continue Reading
Key Insights from the Upcoming Press Conference on Assault Case
Important Press Conference on Recent Assault Case Attorneys from Matheson & Associates, PLLC are set to hold an impactful press conference aimed at shedding light on a serious incident involving truck drivers engaged in Hurricane Helene cleanup efforts. This incident has raised significant concerns about safety and racial tensions. Understanding the Incident On an...
Continue Reading
Couche-Tard Clarifies Intentions Amid Seven & i Interest
Alimentation Couche-Tard Addresses Acquisition Negotiations In recent discussions reported by Japanese media, Alimentation Couche-Tard has made it clear that they are not pursuing a hostile takeover of Seven & i Holdings. Chairman Alain Bouchard emphasized that their strategy focuses on securing a collaborative acquisition approach, rather than a forced or antagonistic...
Continue Reading
Legend Biotech Maintains Strong Outlook Despite Sales Fluctuations
Overview of Legend Biotech's Market Performance Legend Biotech Corp. (NASDAQ: LEGN) has been the focus of investor attention lately, with analysts maintaining a Buy rating and a price target of $91. This confidence stems from recent sales data for CARVYKTI, a treatment for multiple myeloma, which saw impressive performance in its latest quarter. CARVYKTI Sales Surpass...
Continue Reading
Transforming Alzheimer's Diagnostics: New Guidelines Unveiled
New Era in Alzheimer's Disease Diagnosis In a significant advancement for the diagnosis of Alzheimer’s disease and related cognitive impairments, a comprehensive set of clinical practice guidelines has been introduced, marking a pivotal moment for both primary and specialty care. This newly established guideline serves as a beacon for healthcare providers, ensuring they...
Continue Reading